Keyword: Valeant Pharmaceuticals
Repeated drug price hikes have caught plenty of criticism lately, but the attention isn't dissuading everyone.
Valeant partners with Cosmo Pharmaceuticals on ulcerative colitis med Uceris. But in the IBS arena, the teammates may soon be at odds.
Payer discounts are likely to grow even if midterm elections revive attacks on the industry—and investors should be worried about that, analysts say.
Sick of dealing with generic drug shortages and price increases, five large U.S. health systems are forming their own drugmaker.
Valeant and Pershing Square are one step closer to putting years of insider trading allegations in the past.
Valeant and Pershing Square thought they had a settlement with angry investors, but a judge is hauling them to court to defend its fairness.
Valeant will pay $96.25 million and Pershing Square will pay $193.75 million to settle insider trading allegations.
Valeant and former activist partner Bill Ackman may once again be thwarted in their efforts to get insider trading claims against them tossed.
Valeant's third-quarter results provided a welcome dose of good news as the company works to execute its lengthy turnaround.
After paying $1 billion for Sprout and its controversial female libido pill Addyi, Valeant is giving up.